Latest Updates & News
FDA Approves New Drug to Treat Niemann-Pick Disease, Type C
For Immediate Release: September 24, 2024 Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kilograms. “This is the second treatment the FDA has approved for NPC within the span of a week....
FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia
For Immediate Release: September 26, 2024 Español Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long...
What Does FDA Approve? Part 2
[embedded content] Español 中文 한국의 Tagalog Tiếng Việt Is It Really "FDA Approved"? Part 2. Here are 10 more facts about how the FDA works to protect public health. Fact #11: The FDA regulates dermal fillers as medical devices. Dermal fillers are gel-like substances injected under the skin to create a smoother or fuller appearance in the lips, face, or back of...
New Hope for Stomach Cancer: Combining Immunotherapy and Chemotherapy Before Surgery
What Did the Research Discover? Gastric and gastroesophageal junction (G/GEJ) cancers are among the deadliest cancers, and while immunotherapy has become a standard treatment for advanced cases, its role in earlier-stage disease is not well understood. The PANDA trial investigated whether neoadjuvant (before surgery) immunotherapy combined with chemotherapy could...
Elafibranor: A Promising New Treatment for Primary Biliary Cholangitis
What Did the Research Discover? Primary biliary cholangitis (PBC) is a rare liver disease that gradually damages the bile ducts, leading to liver scarring. If left untreated, it can progress to cirrhosis and severe liver disease. The current first-line treatment, ursodeoxycholic acid (UDCA), does not work for up to 40% of patients, and the second-line option,...
Effective Treatments for Post-Inflammatory Hyperpigmentation in People with Darker Skin Tones
What Did the Research Discover? Post-inflammatory hyperpigmentation (PIH) is a condition where dark spots appear on the skin after an injury, inflammation, or irritation. It is especially challenging to treat in people with darker skin tones (Fitzpatrick skin types IV-VI) because their skin naturally has more melanin, which can make treatments more difficult and...